Literature DB >> 27203036

Survey of Treatment Costs to Hepatitis C in China.

Z P Duan1, H Y Zhou1, C Duan1, Z Wang1, Y Chen2, S J Zheng2, S Liu2, A Tang3, H Li4.   

Abstract

Year:  2014        PMID： 27203036     DOI： 10.1016/j.jval.2014.08.515

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  3 in total

1.  Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.

Authors:  Hai Chen; Lijun Chen
Journal:  PLoS One       Date:  2017-04-05       Impact factor: 3.240

Review 2.  Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China.

Authors:  Qing Xie; Jian-Wei Xuan; Hong Tang; Xiao-Guang Ye; Peng Xu; I-Heng Lee; Shan-Lian Hu
Journal:  World J Hepatol       Date:  2019-05-27

3.  Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.

Authors:  Yun Lu; Xiuze Jin; Cheng-A-Xin Duan; Feng Chang
Journal:  PLoS One       Date:  2018-04-10       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.